Retracted: PHOX2B Is Associated with Neuroblastoma Cell Differentiation

Abstract

Cancer Biotherapy and Radiopharmaceuticals (CBR)

officially retracts the article entitled, “PHOX2B Is Associated with Neuroblastoma Cell Differentiation,” by Liqun Yang, Xiao-Xue Ke, Fan Xuan, Juan Tan, Jianbing Hou, Mei Wang, Hongjuan Cui, and Yundong Zhang (Cancer Biother Radiopharm 2016;31(2):44–51; doi: 10.1089/cbr.2015.1952).

Readers are advised that the CBR editorial office received a request via email from the first author, Dr. Liqun Yang, to replace Figure 3, indicating, “This article contains some errors in figure 3. In figure 3A (RA-7d) and figure 3C, we mixed up images from different groups when we prepared the figure. Unfortunately, these mistakes were not corrected when we submitted the manuscript.” This request came after the appearance of a comment posted to the PubPeer platform.¹

The publisher of the journal made several attempts to contact the authors' institutions to inquire about the veracity of the study and the claimed error, and though a reply was eventually received, it did not appear to be official institutional documentation and was not signed by an institutional official's name but rather only by the institutional name, nor did it provide a comprehensive defensible explanation, rendering it unacceptable (see Fig. R1). The Publisher responded to all authors and to the sender of the “declaration” by stating that the document was not admissible and that the article would be officially retracted. No further response or rebuttal was received.

FIG. R1.

 Insufficient declaration letter received by Editor and publisher.

Cancer Biotherapy & Radiopharmaceuticals

is committed to upholding the rigorous standards of scientific publishing and the veracity of the literature.

Reference

1. Actinopolyspora biskrensis. https://pubpeer.com/publications/C4F159C77D012DDDB38D6B930B12AA?utm_source=Chrome&utm_medium=BrowserExtension&utm_campaign=Chrome